In the available retrospective studies, some researchers believe that I131 treatment actually worsens the prognosis of patients.[11] Currently, radioactive iodine therapy is only recommended for thyroglossal duct cancer in combination with ipsilateral thyroid cancer and lymph node metastases.[23] The most common genetic mutation in thyroid cancer is the BRAF mutation, which accounts for about 45% of papillary thyroid cancers,[32] and the most common BRAF family variant in thyroid cancer is BRAF V600E in the BRAF1 gene. This evidence concerns the gene BRAF and thyroid gland papillary carcinoma.